FluoGuide (OM:FLUO) - Stock Price, News & Analysis

FLUO Stock Overview

A clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark.

About the company

FLUO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 75.3% below our estimate of its fair value

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (DKK383K)

Shareholders have been diluted in the past year

Does not have a meaningful market cap (SEK584M)

+ 1 more risk

FluoGuide A/S Competitors

Oncopeptides

OM:ONCO

kr688.6m

Medivir

OM:MVIR

kr361.9m

Hamlet BioPharma

NGM:HAMLET B

kr822.0m

Nanologica

OM:NICA

kr281.9m

Price History & Performance

Summary of all time highs, changes and price drops for FluoGuide
Historical stock prices
Current Share Price	kr47.90
52 Week High	kr99.80
52 Week Low	kr41.15
Beta	0
1 Month Change	-2.74%
3 Month Change	-6.08%
1 Year Change	-43.78%
3 Year Change	-57.76%
5 Year Change	858.00%
Change since IPO	764.62%

Recent updates

Shareholder Returns

	FLUO	SE Biotechs	SE Market
7D	-2.7%	2.0%	-0.9%
1Y	-43.8%	10.1%	14.2%

Return vs Industry: FLUO underperformed the Swedish Biotechs industry which returned 10.1% over the past year.

Return vs Market: FLUO underperformed the Swedish Market which returned 14.2% over the past year.

Price Volatility

Is FLUO's price volatile compared to industry and market?
FLUO volatility
FLUO Average Weekly Movement	9.0%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	12.9%
10% least volatile stocks in SE Market	3.5%

Stable Share Price: FLUO has not had significant price volatility in the past 3 months.

Volatility Over Time: FLUO's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	8	Morten Albrechtsen	fluoguide.com

FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology.

FluoGuide A/S Fundamentals Summary

How do FluoGuide's earnings and revenue compare to its market cap?
FLUO fundamental statistics
Market cap	kr584.28m
Earnings (TTM)	-kr55.67m
Revenue (TTM)	kr586.39k

996.4x

P/S Ratio

-10.5x

P/E Ratio

Is FLUO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FLUO income statement (TTM)
Revenue	kr.383.00k
Cost of Revenue	kr.0
Gross Profit	kr.383.00k
Other Expenses	kr.36.75m
Earnings	-kr.36.36m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 29, 2024

Earnings per share (EPS)	-2.98
Gross Margin	100.00%
Net Profit Margin	-9,494.26%
Debt/Equity Ratio	177.8%

How did FLUO perform over the long term?

See historical performance and comparison

FLUO Stock Overview

Rewards

Risk Analysis

FluoGuide A/S Competitors

OM:ONCO

kr688.6m

OM:MVIR

kr361.9m

NGM:HAMLET B

kr822.0m

OM:NICA

kr281.9m

Price History & Performance

Recent News & Updates

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Recent updates

FluoGuide A/S to Report Fiscal Year 2024 Final Results on Feb 27, 2025

Less than half of directors are independent

Less than half of directors are independent

FluoGuide A/S Approves Board Changes

New major risk - Revenue and earnings growth

No longer forecast to breakeven

FluoGuide A/S to Report Q2, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

FluoGuide A/S Provides Strategic Update and Outlines Development Plans Towards Commercialization of FG001

New minor risk - Shareholder dilution

FluoGuide A/S Announces FG001 Meets Primary Endpoint in Phase LLB Trial in Aggressive Brain Cancer

FluoGuide A/S Confirms Positive Topline Results from Phase IIa Trial of FG001 in Head & Neck Cancer at International Academy of Oral Oncology Conference

Pfluoguide A/S Provides Positive Interim Data from Phase Lla Trial of Fg001 in Head & Neck Cancer Presented as A Case Report At the World Molecular Imaging Congress in Prague

New minor risk - Profitability

Fluoguide A/S Announces Completion of Patient Enrollment and Treatment in the Phase IIb Trial with Fg001 in Patients with Aggressive Brain Cancer

FluoGuide A/S Announces Positive Interim Results from Phase IIa Trial of FG001 in Head & Neck Cancer

Fluoguide A/S Announces Positive Topline Results from Phase Iia Trial of Fg001 in Lung Cancer

FluoGuide A/S to Report Q3, 2023 Results on Nov 29, 2023

FluoGuide A/S Appoints Ole Larsen as Chief Financial Officer

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

FluoGuide A/S Releases Positive Interim Result of FG001 in Head and Neck Cancer

FluoGuide A/S, Annual General Meeting, Mar 21, 2023

FluoGuide A/S to Report Fiscal Year 2022 Results on Feb 28, 2023

FluoGuide A/S Enrolls First Patient in the Phase IIa Trial in Head and Neck Cancer

FluoGuide A/S Reaches Milestone with FG001 for Phase III Clinical Supply

FluoGuide A/S Releases Positive Interim Result of FG001-CT002

FluoGuide A/S Enrolls the First Patient in the Phase IIb Trial in Aggressive Brain Cancer

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide A/S Presents the Outstanding Clinical Data from the Completed Phase I/IIa Trial with FG001 in Patients with Aggressive Brain Cancer Undergoing Surgery, At the World Molecular Imaging Congress

FluoGuide A/S Ordinary Shares to Be Deleted from OTC Equity

FluoGuide A/S Receives Approval from the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Head and Neck Cancer

FluoGuide Announces CFO Changes

FluoGuide Receives Permission to Start Phase IIb Trial in Aggressive Brain Cancer

Fluoguide A/S Update on Fg001's Clinical Development

FluoGuide Submits a Clinical Trial Application (CTA) to the Danish Medicines Agency to Initiate Phase II Trial with FG001 in Head and Neck Cancer

FluoGuide Publish the Presentation of FG001 Results from the First Clinical Trial in Aggressive Brain Cancer

We're Hopeful That FluoGuide (STO:FLUO) Will Use Its Cash Wisely

FluoGuide A/S Announces Positive Top Line Result from Ongoing Clinical Phase I/II Trial

FluoGuide (STO:FLUO) Is In A Good Position To Deliver On Growth Plans

FluoGuide Submits Clinical Trial Application to the Danish Medicines Agency to Initiate Phase Ii Trial with Fg001 in Lung Cancer

Fluoguide Proceeds to Seventh Dose Level with Fg001 in the Ongoing Clinical Phase I/II Trial Following Continued Improvement of Tumor Illumination with Increasing Doses

FluoGuide Announces Regulatory Approval from Swedish Authorities to Commence Phase II Clinical Trial with FG001 in Guiding Surgery of High Grade Glioma in Sweden

FluoGuide A/S Announces Publication of Promising Preclinical Data on FG001 Effect in Treatment of Cancer

FluoGuide A/S Announces Promising Preclinical Data with Fg002 Technology in Guiding Surgical Removal of Cancer

FluoGuide has Received Green Light to Proceed to the Next Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients Undergoing Surgical Treatment of High Grade Glioma

FluoGuide Receives Approval to Commence with FG001 in Evening Dosing in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

FluoGuide A/S Acquires Rights to Photothermal Therapy Using FG001

Companies Like FluoGuide (STO:FLUO) Are In A Position To Invest In Growth

Dose Escalation Committee Approves FluoGuide A/S's Initiation of the Fourth Dose Level in the Ongoing Clinical Phase I/II Trial Evaluating Safety and Efficacy of Fg001 in Patients with High Grade Glioma Undergoing Neurosurgery

Chairman Arne Ferstad has left the company

Fluoguide A/S Announces Management Changes At the Annual General Meeting Held on February 9, 2021

Fluoguide A/S Announces Publication of Two Patent Applications Covering the Company's uPAR Technology Platform for Improving Surgery

FluoGuide A/S to Report Nine Months, 2021 Results on Nov 24, 2021

New 90-day high: kr.132

FluoGuide A/S Gets Green Light to Proceed to Second Dose Level with FG001 in the Ongoing Clinical Phase I/II Trial in Patients with High Grade Glioma

New 90-day low: kr.46.20

FluoGuide A/S Announces First Patient Enrolled in the Phase I/II Clinical Trial Testing FG001 in Patients with High Grade Glioma

FluoGuide Appoints Henrik Moltke as Chief Financial Officer, Effective December 2020

New 90-day high - kr.40.00